Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $9.00 Consensus Price Target from Analysts

Senti Biosciences, Inc. (NASDAQ:SNTI) has been assigned a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $9.00.

SNTI has been the topic of a number of research analyst reports. HC Wainwright started coverage on shares of Senti Biosciences in a research report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 target price on the stock. Chardan Capital raised their price objective on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Leerink Partners began coverage on Senti Biosciences in a research report on Friday, November 21st. They set an “outperform” rating and a $6.00 price objective on the stock. Wall Street Zen raised Senti Biosciences to a “sell” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd.

Senti Biosciences Stock Performance

SNTI opened at $0.93 on Wednesday. Senti Biosciences has a fifty-two week low of $0.80 and a fifty-two week high of $5.10. The stock has a fifty day moving average of $1.24 and a 200-day moving average of $1.55. The company has a market capitalization of $24.46 million, a P/E ratio of -0.28 and a beta of 2.13.

Senti Biosciences (NASDAQ:SNTI) last released its earnings results on Thursday, November 13th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). On average, equities research analysts predict that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

A number of institutional investors have recently added to or reduced their stakes in SNTI. Armistice Capital LLC acquired a new position in Senti Biosciences in the 2nd quarter valued at approximately $1,883,000. Geode Capital Management LLC grew its stake in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Senti Biosciences in the third quarter valued at $117,000. 25.70% of the stock is owned by institutional investors.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.